ANAHEIM, Calif., Feb. 16, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that Standard & Poor's (S&P) will add the Company to the S&P SmallCap 600 Index effective after the close of the U.S. financial markets on February 17, 2011.
"Our inclusion in the S&P SmallCap 600 Index reflects our consistent financial performance, and will serve to increase our visibility within the investment community as we continue our efforts to grow sales for H.P. Acthar® Gel for the treatment of acute exacerbations of multiple sclerosis, infantile spasms and nephrotic syndrome," said Don M. Bailey, President and CEO of Questcor.
S&P indices are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from two indications: the treatment of acute exacerbations of multiple sclerosis in adults and the treatment of infantile spasms in children under two years of age. Questcor is also implementing plans to commercialize Acthar for use in treating nephrotic syndrome, another on-label indication. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.
|SOURCE Questcor Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved